MediPharm Labs Achieves Court Victory Over Dissident Claims
In a significant development, MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), a pioneer in precision-based cannabinoid pharmaceuticals, recently received favorable news from the Ontario Superior Court of Justice. The court dismissed an application brought forth by Apollo Technology Capital Corporation and Nobul Technologies Inc., which sought to undermine the integrity of MediPharm's Annual and Special Meeting of Shareholders.
Understanding the Court's Decision
The application had requested the appointment of a third-party independent chair for the upcoming shareholder meeting, scheduled for June 16. The claim was founded on allegations that MediPharm intended to invalidate proxies, which could jeopardize a fair meeting process. However, upon review, the court found no merit in these claims and determined that MediPharm's proposed chair would conduct the meeting fairly.
The court's ruling emphasized that the evidence presented did not support the need for a third-party chair. This decision reinforces the legitimacy of MediPharm's governance and its commitment to transparent shareholder processes.
The Court's Findings on Apollo's Conduct
During the proceedings, the court scrutinized the actions of Apollo's principal, Regan McGee. Findings revealed troubling behavior, including threats from Mr. McGee to release defamatory statements about a member of MediPharm’s board and claims of securities fraud against the company. This backdrop of aggressive tactics led the court to view the application as an attempt to disrupt MediPharm's operations rather than a legitimate concern for shareholder welfare.
MediPharm's Commitment to Shareholder Engagement
In light of the recent court ruling, MediPharm remains dedicated to fostering a fair shareholder meeting process, adhering to its foundational documents and legal requirements. The company urges all shareholders to participate in the voting process using only the designated GREEN proxy cards to ensure their voices are heard during the meeting. This commitment to active shareholder engagement highlights MediPharm's ongoing pursuit of transparency and accountability.
Additionally, shareholders are encouraged to contact their brokers to obtain a unique control number associated with their votes. Having this information readily available is crucial in making an informed decision and supporting the candidates put forth by the company’s Board of Directors.
Details on MediPharm Labs and Its Operations
Founded in 2015, MediPharm Labs has carved a niche in the pharmaceutical sector as a trusted producer of high-quality cannabis products. The company employs advanced manufacturing practices and boasts a Good Manufacturing Practices certified facility that adheres to ISO standards. With an emphasis on purity and precision, MediPharm develops a range of cannabinoid-based products targeted at both local and international medical markets.
Notably, in 2021, MediPharm obtained a license from Health Canada, making it the only North American company certified for large-scale extraction of natural cannabinoids under GMP regulations. This milestone marked the beginning of its pathway towards compliance with U.S. Food and Drug Administration standards for foreign drug manufacturing.
Recent Expansion Steps
In 2023, the acquisition of VIVO Cannabis Inc. broadened MediPharm’s market reach, enabling the company to serve medical cannabis patients across various regions, including Canada, Australia, and Germany. With VIVO’s ecommerce platform and medical clinics, MediPharm enhances access to its products and promotes ongoing education around medical cannabis usage.
Continually striving for compliance, MediPharm operates in full respect of the laws governing the jurisdictions in which it functions, ensuring that innovative and safe products are delivered to its customers.
Shareholder Voting Assistance
For any inquiries related to proxy execution or voting assistance, shareholders are encouraged to reach out to Sodali & Co. The firm has dedicated resources to aid in the voting process:
North American Toll-Free Number: 1.888.777.2059
International Inquiries: 1.289.695.3075
Email: assistance@investor.sodali.com
Toll-Free Facsimile: 1.877.218.5372
Frequently Asked Questions
What was the outcome of the court proceedings involving MediPharm?
The Ontario Superior Court fully dismissed the application from Apollo Technology Capital Corporation and Nobul Technologies Inc., allowing MediPharm to proceed with its planned shareholder meeting without the need for a third-party chair.
Why was the independent chair requested for the shareholder meeting?
The Applicants claimed MediPharm was attempting to invalidate proxies and therefore required a third-party chair to ensure fairness at the meeting.
What actions did the court take regarding Mr. McGee?
The court highlighted Mr. McGee's threatening behavior and lack of credible evidence in his claims against MediPharm, impacting the integrity of the Applicants' case.
How can shareholders participate in the upcoming meeting?
Shareholders are advised to vote using the GREEN proxy or voting instruction card to support the company’s nominated directors and resolutions.
What expansions has MediPharm Labs experienced recently?
MediPharm has expanded its reach through the acquisition of VIVO Cannabis Inc., enhancing access to medical cannabis markets in Canada, Australia, and Germany.
